Under last POA, by .3!! Over for now, with no room for error. I thought product launches were where we can make the money! Still getting used to NNI analytics.
Quit being so cynical. Obviously, the Basal reps listened to all of the GLP reps that made all the bonus cash the first 9 months of the year, and have taken those strategies to help 80% of them to be above goal this POA. And the GLP reps have just forgotten to show AND tell clinically. So obvious. Not that hard to figure out. Now someone will probably doubt this and throw some crazy theory out there about “capping bonuses” or something.
Its quite obvious Novo had the whole year payout planned out to pay the GLP reps the first half and the insulin reps the 2nd half. Overall, the GLP reps were payed more but they did change how they were measured quarterly causing payouts for GLP reps to be spread out. Overall, most reps will be paid relatively close to the same amount. A few exceptions on both ends of the spectrum but make no mistake, Novo normalizes the majority of us.
